{"id":"NCT04668352","sponsor":"Restorbio Inc.","briefTitle":"A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly","officialTitle":"A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-15","primaryCompletion":"2019-12-02","completion":"2019-12-02","firstPosted":"2020-12-16","resultsPosted":"2021-06-23","lastUpdate":"2021-06-23"},"enrollment":1024,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Tract Infections"],"interventions":[{"type":"DRUG","name":"Dactolisib","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dactolisib 10mg once daily","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.","primaryOutcome":{"measure":"Percentage of Subjects With Clinically Symptomatic Respiratory Illness","timeFrame":"Week 0-16","effectByArm":[{"arm":"Placebo","deltaMin":125,"sd":null},{"arm":"Dactolisib 10mg Once Daily","deltaMin":134,"sd":null}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["New Zealand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":510},"commonTop":["Therapeutic response unexpected","Diarrhoea","Headache","Fall","Urinary tract infection"]}}